Cough and Cold Preparations Market Report 2025

The cough and cold preparations market size has grown strongly in recent years. It will grow from $84.7 billion in 2024 to $88.99 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, strong economic growth in emerging markets, and rise in healthcare expenditure.

The cough and cold preparations market size is expected to see steady growth in the next few years. It will grow to $106.35 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to the increased popularity of e-cigarettes/ vaping, rising obesity levels, large pool of undiagnosed population, and government initiatives. Major trends in the forecast period include the use of probiotics to treat asthma, advanced bronchodilators launched, new product launches, mergers and collaborations in the market, increasing demand for personalized medicines, demand for aerosol respiratory drugs, the rise of generic respiratory drugs, and combination drug therapy to treat COPD.

The growth of the cough and cold preparations market is anticipated to be fueled by the rising incidence of allergies in the forecast period. Respiratory allergies, including those triggered by pollen, dust, mold, and pet dander, are on the ascent due to contaminated outdoor and indoor air. Cough and cold preparations are commonly used to address allergies that manifest as coughs and respiratory issues. For example, the European Academy of Allergy and Clinical Immunology projects that by 2025, one in every three people in the European Union will be affected by allergies. This surge in respiratory allergies is expected to drive demand for cough and cold preparations, positively influencing market growth.

The growing geriatric population is anticipated to drive the expansion of the cough and cold preparations market in the coming years. The geriatric population refers to the ratio of individuals aged 65 and older to those aged 18 to 64 who are employed. Older adults generally have weaker immune systems, making them more prone to respiratory infections, such as coughs and colds. This increased susceptibility creates a higher demand for cough and cold remedies. For example, a report published by the US-based Pew Research Center Organization in January 2024 stated that the geriatric population is projected to grow from 0.2% in 2024 to 0.5% in 2054. Thus, the rise in the geriatric population is propelling the growth of the cough and cold preparations market.

Advancements in technologies are playing a pivotal role in shaping the global pharmaceutical sector, and this impact extends to cold and cough preparations. As outlined in a global life sciences report by Deloitte, various cutting-edge technologies are driving the life sciences sector, including the pharmaceutical domain. Some of these transformative technologies include AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine. AI technology is being harnessed for diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is facilitating the emergence of new business models and enhancing customer experiences. Biomarkers, which are biological indicators objectively measured and evaluated for various processes, are increasingly being utilized in the drug development process to expedite product launches.

Leading companies in the cough and cold preparations market are introducing new products, such as clean over-the-counter (OTC) kids' medicine, to address the growing consumer demand for safer, natural, and effective remedies. Clean OTC kids' medicine refers to non-prescription medications specifically designed for children, focusing on natural and minimal ingredient formulations. These products aim to relieve common cold and cough symptoms while avoiding harmful additives, appealing to parents who prioritize safe options for their children. For instance, in September 2023, Genexa, a U.S.-based pharmaceutical company, launched two new clean OTC medicines: Kids’ Multi-Symptom Cold and Flu and the Kids Daytime Nighttime Cough Relief Value Pack, providing effective relief from common cold and flu symptoms in children. The Multi-Symptom Cold & Flu formulation temporarily suppresses cough, reduces fever, and relieves minor aches and pains without artificial ingredients, making it a cleaner choice for parents mindful of additives. Additionally, the Daytime and Nighttime Cough Relief Value Pack provides tailored options for non-drowsy daytime relief and nighttime comfort, ensuring comprehensive care around the clock.

The cold and cough preparations market is subject to regulatory oversight by authorities, such as the Food and Drug Administration (FDA) in the United States. An example of regulatory action is the FDA's restriction on the use of codeine in children. Codeine, although approved for pain and cough treatment, poses serious risks, including the potential for slowed or difficult breathing, and can be fatal. The FDA has recognized a higher risk of these adverse effects in children under the age of 12, leading to restrictions on the use of codeine even in some older children. Single-ingredient codeine is FDA-approved solely for use in adults. Additionally, the FDA recommends against the use of codeine in breastfeeding mothers due to the potential harm it may pose to their infants. This regulatory intervention reflects a commitment to ensuring the safety of pharmaceutical products, especially those intended for vulnerable populations such as children and breastfeeding mothers.

Major companies operating in the cough and cold preparations market include Johnson & Johnson, GlaxoSmithKline plc, Procter & Gamble, Bayer AG, Reckitt Benckiser Group plc, Novartis AG, Perrigo Company, Sun Pharmaceutical Industries Ltd., Prestige Consumer Healthcare, Blackmores Limited, AFT Pharmaceuticals, Dexa Medica, Glenmark Pharmaceuticals Limited, Wockhardt Ltd, Apnar Pharma LP, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings, Inc, Nichi-Iko Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Co., Ltd., China National Pharmaceutical Group Co., Ltd, Shanghai Anovent Pharma, Shanghai Acebright Pharmaceuticals Group Co., Ltd, China Meheco Group Co., Ltd., Merck & Co, Abbott Laboratories, Boehringer Ingelheim, Roche Holding AG, Vectura Group, Pfizer, Mylan, Teva Pharmaceutical Industries Ltd, Sanofi, W. K. Buckley Limited, BENYLIN, Sanfer, PROBIOMED, PiSA, EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, AstraZeneca, Neopharma, Regal Pharmaceuticals, Adcock Ingram, Aspen Pharmacare.

North America was the largest region in the cold and cough preparation market share in 2024. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the cough and cold preparations market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cough and cold preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Cold and cough preparations encompass medications designed to alleviate symptoms associated with these conditions. These drugs target receptors where the infecting virus attaches, countering the receptor's action, eradicating viral infection, and reducing congestion by breaking down mucus and expanding constricted bronchioles.

Primary drug categories in cold and cough preparations consist of antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and other similar treatments. Antihistamines mitigate histamine's effects and are commonly used to address allergies. Varieties include bronchodilators, anticholinergic, and pulmonary antihypertensives. These medications are available in various forms such as oral syrups, tablets, nasal drops, lozenges, and others. Distribution occurs through hospital pharmacies, retail pharmacies, drug stores, and similar channels.

The cold and cough preparations market research report is one of a series of new reports that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.